close

Agreements

Date: 2017-06-08

Type of information: Nomination

Compound:

Company: Vertex Pharmaceuticals (USA - MA)

Therapeutic area: Rare diseases - Genetic diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On June 8, 2017, shareholders of Vertex Pharmaceuticals elected Alan M. Garber, as an independent member of its board of directors. Dr. Garber is Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical School, a Professor of Economics in the Faculty of Arts and Sciences, a Professor of Public Policy in the Harvard Kennedy School of Government, and a Professor in the Department of Health Policy and Management in the Harvard T.H. Chan School of Public Health.
  • Prior to joining Harvard in 2011, Dr. Garber was the Henry J. Kaiser Jr. Professor, a Professor of Medicine, and a Professor (by courtesy) of Economics, Health Research and Policy, and of Economics in the Graduate School of Business at Stanford University. He is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society of Clinical Investigation, the Association of American Physicians and the Board on Science, Technology, and Economic Policy at the National Academies. Dr. Garber is also a Fellow of the American College of Physicians and the Royal College of Physicians and a Research Associate with the National Bureau of Economic Research. He also has served as a member of the National Advisory Council on Aging at the National Institutes of Health, the Board of Health Advisers of the Congressional Budget Office and Chair of the Medicare Evidence Development and Coverage Advisory Committee at the Centers for Medicare and Medicaid Services.
  • Dr. Garber holds an A.B. summa cum laude, an A.M. and a Ph.D. in Economics from Harvard University, as well as an M.D. with research honors from Stanford University.

Financial terms:

Latest news:

Is general: Yes